Tvardi Therapeutics (TVRD) Other Operating Expenses (2019 - 2026)

Tvardi Therapeutics has reported Other Operating Expenses for 6 years, with the latest figure at -$1.2 million in Q1 2026.

• Quarterly Other Operating Expenses fell 90.54% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.8 million (down 107.21% YoY) and the FY2025 annual result came in at -$5.2 million, down 120.57% from the prior year.
• Other Operating Expenses improved to -$1.2 million in Q1 2026 per TVRD's latest filing, from -$1.2 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $3.1 million in Q3 2022 and troughed at -$2.0 million in Q2 2025.
• A 5-year average of $340750.0 and a median of $222000.0 in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Operating Expenses increased 24.46% in 2023, then tumbled 1134.76% in 2025.
• Over 5 years, Other Operating Expenses stood at $2.1 million in 2022, then slumped by 71.46% to $608000.0 in 2023, then tumbled by 365.62% to -$1.6 million in 2024, then increased by 22.6% to -$1.2 million in 2025, then grew by 3.36% to -$1.2 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$1.2 million, -$1.2 million, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.